Patents by Inventor Clare L. M. LeGuyader

Clare L. M. LeGuyader has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210047338
    Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.
    Type: Application
    Filed: April 9, 2020
    Publication date: February 18, 2021
    Applicants: The Regents of the University of California, Vybyl Holdings, Inc.
    Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L.M. LeGuyader, Paul A. Bertin
  • Patent number: 10654864
    Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: May 19, 2020
    Assignees: The Regents of the University of California, Elevance Renewable Sciences, Inc.
    Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L. M. LeGuyader, Paul A. Bertin
  • Publication number: 20200046859
    Abstract: The present disclosure generally provides compounds useful as MRI contrast agents. In some aspects, the disclosure provides MRI contrast agents that are chemically modified to have one or more moieties that include hydrophobic portions. In some aspects, the disclosure provides compositions that include such modified MRI contrast agents and a protein, such as albumin or albumin mimetics. Further, the disclosure provides various uses of these compounds and compositions.
    Type: Application
    Filed: April 25, 2018
    Publication date: February 13, 2020
    Inventors: Clare L.M. Leguyader, Nathan Gianneschi, Cassandra E. Callmann, Matthew P. Thompson, Treffly Ditri, Paul A. Bertin
  • Publication number: 20190381179
    Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.
    Type: Application
    Filed: March 19, 2019
    Publication date: December 19, 2019
    Applicants: The Regents of the University of California, Vybyl Holdings, Inc.
    Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L.M. LeGuyader, Paul A. Bertin
  • Patent number: 10286079
    Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: May 14, 2019
    Assignees: The Regents of the University of California, Vybyl Holdings, Inc.
    Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L. M. LeGuyader, Paul A. Bertin
  • Publication number: 20180222915
    Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 9, 2018
    Applicants: The Regents of the University of California, Vybyl Holdings, Inc.
    Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L. M. LeGuyader, Paul A. Bertin
  • Patent number: 10023581
    Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: July 17, 2018
    Assignees: The Regents of the University of California, Vybyl Holdings, Inc.
    Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L. M. LeGuyader, Paul A. Bertin
  • Publication number: 20180000951
    Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.
    Type: Application
    Filed: March 22, 2017
    Publication date: January 4, 2018
    Applicants: The Regents of the University of California, Vybyl, Inc.
    Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L. M. LeGuyader, Paul A. Bertin
  • Publication number: 20170080094
    Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.
    Type: Application
    Filed: September 21, 2016
    Publication date: March 23, 2017
    Applicants: The Regents of the University of California, Vybyl, Inc.
    Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L. M. LeGuyader, Paul A. Bertin